WebMar 1, 2024 · PHESGO is made up of two medicines combined together that belong to a group of medicines called monoclonal antibodies (pertuzumab and trastuzumab). • …
Did you know?
WebMar 2, 2024 · Phesgo is a cancer medicine for treating adults with ‘HER2-positive’ breast cancer (where a protein called HER2 is found on the cancer cells). It is used in combination with other cancer medicines in: patients with early breast cancer (when the cancer has not spread to other parts of the body) at high risk of coming back, after they have surgery; WebAug 25, 2024 · The initial dose of Phesgo™ is 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase administered subcutaneously over approximately 8 minutes, followed every 3 weeks by a dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase administered subcutaneously over approximately 5 minutes ...
WebMay 3, 2024 · Phesgo. Hi I've been on trastuzumub and pertuzumab since March, my last 3 times I've had the phesgo injection in alternate thighs each time, injection only takes 5 … WebExposure to PHESGO can result in embryo-fetal death and birth defects, including oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception
WebPHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti … WebPHESGO can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death PHESGO can also cause asymptomatic decline in LVEF Patients who receive anthracycline after stopping PHESGO may also be at … Treatment regimens for early and metastatic breast cancer, based on pertuzuma… Printable Resources - Dosing & Administration PHESGO® (pertuzumab / trastuzu… Side Effects - Dosing & Administration PHESGO® (pertuzumab / trastuzumab ... PHESGO Access Solutions offers a range of access and reimbursement resource… Trial Information - Dosing & Administration PHESGO® (pertuzumab / trastuzuma…
WebJul 10, 2024 · Side Effects What are the side effects of Phesgo (Hyaluronidase Pertuzumab and Trastuzumab)?. Get emergency medical help if you have signs of an allergic reaction: hives, rash; fever, chills ...
WebJul 27, 2024 · Phesgo is given as an injection under the skin into your thigh. The first dose of Phesgo takes about 8 minutes to inject and each dose after that takes about 5 minutes, … tartan shirt boysWebPHESGO is contraindicated in patients with known hypersensitivity to pertuzumab, or trastuzumab, or hyaluronidase, or to any of its excipients. 5.1 Cardiomyopathy. PHESGO can cause hypertension, arrhythmias, left ventricular cardiac dysfunction, disabling cardiac failure, cardiomyopathy, and cardiac death [see Boxed Warning: Cardiomyopathy]. tartan shirt by foxcroftWebJun 29, 2024 · The FDA has granted approval to phesgo – a combination of pertuzumab (Perjeta), trastuzumab (Herceptin), and hyaluronidase-zzxf – for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early-stage disease. 1 Patients should be … tartan shirt dressWebWhat does PHESGO treat? PHESGO ® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:. use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or … tartan shirt dresses for womenWebNov 1, 2024 · Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection is a sterile, preservative-free, clear to opalescent, and colorless to slightly brownish solution … tartan shift dress with white collarWebJun 29, 2024 · The recommended initial dose of PHESGO is 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase administered subcutaneously over approximately 8 minutes, followed every 3 weeks... tartan shieldWebPhesgo® contains two separate monoclonal antibodies, trastuzumab and pertuzumab. Previously, trastuzumab and pertuzumab were used separately or in combination to provide anti-cance r treatment. Phesgo® combined these two separate monoclonal antibodies into a single injection for use. tartan shirt dress fit and flare